How Bimagrumab Targets Muscle Loss and Obesity From Lab Bench to Clinical Trial
Physician-scientist Lloyd Klickstein walks through the full arc of drug development, using bimagrumab as a case study in fighting sarcopenia and obesity.
Summary
In this two-and-a-half-hour episode, Peter Attia and physician-scientist Lloyd Klickstein trace every step of modern drug development using bimagrumab — an antibody that blocks myostatin and activin signaling — as the central example. Klickstein explains how sarcopenia was chosen as an initial target, how the antibody was engineered and screened, and what early animal data showed regarding dramatic muscle hypertrophy. He then walks through first-in-human studies, Phase 2 lessons on muscle function and nutrition, and a surprising finding: bimagrumab also reduced fat mass and improved type 2 diabetes markers. This pivot led to the BELIEVE trial combining bimagrumab with semaglutide. The conversation also covers the economics of drug development, patent strategy, GMP manufacturing, IND requirements, selective mTORC1 inhibition, and an emerging pharmacologic approach to cancer prevention.
Detailed Summary
Sarcopenia — the progressive loss of muscle mass and strength with age — is one of the most consequential yet under-treated drivers of functional decline and mortality in older adults. Despite its enormous burden, no approved pharmacologic therapy exists. This episode explores why that gap persists and how one drug candidate is trying to close it.
Lloyd Klickstein, a physician-scientist with over 20 years spanning academic medicine and biotechnology, joins Peter Attia to trace the complete life cycle of a drug from target identification to clinical trial. The vehicle is bimagrumab, a monoclonal antibody engineered to block both myostatin and activin type II receptors, two potent inhibitors of skeletal muscle growth. Klickstein explains why follistatin — an earlier attempt at the same pathway — failed, and how the antibody engineering and screening process was designed to maximize selectivity and potency.
Animal proof-of-concept data showed impressive muscle hypertrophy, which justified the substantial capital required to advance to human trials. Early Phase 1 studies established safety and pharmacodynamics. Phase 2 data confirmed improvements in muscle mass, but also revealed something unexpected: significant reductions in fat mass and improvements in type 2 diabetes biomarkers. This metabolic signal reshaped the drug's development trajectory.
The BELIEVE trial subsequently tested bimagrumab in combination with semaglutide, hypothesizing that blocking GLP-1-associated muscle loss while amplifying fat loss could produce a superior body composition outcome compared to semaglutide alone. The conversation also addresses selective mTORC1 inhibition as a geroprotective strategy and a novel pharmacologic approach to cancer prevention.
Throughout, Klickstein contextualizes why drug development takes so long and costs so much — from IND requirements and GMP manufacturing to capital allocation and the critical importance of identifying failures early. The episode is an unusually transparent look at how longevity-relevant science moves from hypothesis to human evidence.
Key Findings
- Bimagrumab blocks myostatin and activin signaling, producing significant skeletal muscle hypertrophy in animal models.
- Phase 2 trials revealed unexpected fat mass reduction and improved type 2 diabetes markers alongside muscle gains.
- The BELIEVE trial combines bimagrumab with semaglutide to preserve muscle while maximizing fat loss.
- Selective mTORC1 inhibition is discussed as a promising but difficult-to-test geroprotective strategy.
- Early failure detection is the single most cost-effective lever in drug development, given multi-hundred-million-dollar trial costs.
Methodology
This is a long-form podcast interview rather than a primary research publication. Content draws on Klickstein's firsthand experience leading translational research on bimagrumab across preclinical, Phase 1, and Phase 2 stages. Clinical trial data referenced include first-in-human dosing studies, Phase 2 muscle and metabolic outcomes, and the BELIEVE combination trial with semaglutide.
Study Limitations
This summary is based on the video abstract and chapter timestamps only, not a peer-reviewed publication; specific numerical trial results are not independently verifiable from this source. The BELIEVE trial results are discussed but the trial may still be ongoing or unpublished in full. The conversation reflects one expert's perspective and may not capture the complete regulatory or competitive landscape for myostatin-targeting therapies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: